The cardiovascular drug developer, which had raised $94m from investors including Sanofi, priced its initial public offering considerably below the range set last week.
MyoKardia, a US-based developer of treatments for cardiovascular disease backed by pharmaceutical firm Sanofi, will raise $54.4m in its initial public offering when it floats on Nasdaq today.
The company priced almost 5.44 million shares at $10 each, considerably less than its $86m target when it initially filed for the IPO last month, as well as the $15 to $17 range set last week, when it planned to issue almost 4.7 million shares.
Sanofi’s involvement is also set…
